We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $66.19, marking a -1.88% move from the previous day. This move lagged the S&P 500's daily gain of 0.23%. Meanwhile, the Dow gained 0.85%, and the Nasdaq, a tech-heavy index, lost 0.08%.
Heading into today, shares of the HIV and hepatitis C drugmaker had gained 1.02% over the past month, lagging the Medical sector's gain of 1.17% and the S&P 500's gain of 3.84% in that time.
GILD will be looking to display strength as it nears its next earnings release, which is expected to be July 30, 2019. On that day, GILD is projected to report earnings of $1.73 per share, which would represent a year-over-year decline of 9.42%. Our most recent consensus estimate is calling for quarterly revenue of $5.52 billion, down 2.24% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.90 per share and revenue of $22.07 billion, which would represent changes of +3.45% and -0.25%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for GILD. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.03% higher within the past month. GILD is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that GILD has a Forward P/E ratio of 9.78 right now. Its industry sports an average Forward P/E of 23.14, so we one might conclude that GILD is trading at a discount comparatively.
We can also see that GILD currently has a PEG ratio of 3.01. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.88 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 61, putting it in the top 24% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $66.19, marking a -1.88% move from the previous day. This move lagged the S&P 500's daily gain of 0.23%. Meanwhile, the Dow gained 0.85%, and the Nasdaq, a tech-heavy index, lost 0.08%.
Heading into today, shares of the HIV and hepatitis C drugmaker had gained 1.02% over the past month, lagging the Medical sector's gain of 1.17% and the S&P 500's gain of 3.84% in that time.
GILD will be looking to display strength as it nears its next earnings release, which is expected to be July 30, 2019. On that day, GILD is projected to report earnings of $1.73 per share, which would represent a year-over-year decline of 9.42%. Our most recent consensus estimate is calling for quarterly revenue of $5.52 billion, down 2.24% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.90 per share and revenue of $22.07 billion, which would represent changes of +3.45% and -0.25%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for GILD. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.03% higher within the past month. GILD is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that GILD has a Forward P/E ratio of 9.78 right now. Its industry sports an average Forward P/E of 23.14, so we one might conclude that GILD is trading at a discount comparatively.
We can also see that GILD currently has a PEG ratio of 3.01. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.88 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 61, putting it in the top 24% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.